Q-omics provides the consensus-scored LIMD2 profile across patient tissues and cancer cell-line models. LIMD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LIMD2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LIMD2 protein abundance shows 21,534 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where LIMD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIMD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIMD2 survival associations across molecular data types. LIMD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIMD2 RNA expression–survival associations across cancer types. High LIMD2 expression shows unfavorable associations in KIRC and LGG, but favorable associations in HNSC, ESCA, UCEC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for LIMD2 RNA expression.
This table summarizes LIMD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIMD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIMD2 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, BLCA and UCEC. The KIRC box plot shows higher LIMD2 RNA expression in tumor versus normal tissue (log2 FC = +1.677, t-test p < 0.001).
This table shows molecular features associated with LIMD2 in patient tissues and cancer cell lines. In patient samples, LIMD2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIMD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
